Literature DB >> 18284803

Quantitative nondestructive methods for the determination of ticlopidine in tablets using reflectance near-infrared and Fourier transform Raman spectroscopy.

C K Markopoulou1, J E Koundourellis, M G Orkoula, C G Kontoyannis.   

Abstract

Two different nondestructive spectroscopy methods based on near-infrared (NIR) and Fourier transform (FT) Raman spectroscopy were developed for the determination of ticlopidine-hydrochloride (TCL) in pharmaceutical formulations and the results were compared to those obtained by high-performance liquid chromatography (HPLC). An NIR assay was performed by reflectance over the 850-1700 nm region using a partial least squares (PLS) prediction model, while the absolute FT-Raman intensity of TCL's most intense vibration was used for constructing the calibration curve. For both methodologies the spectra were obtained from the as-received film-coated tablets of TCL. The two quantitative techniques were built using five "manual compressed" tablets containing different concentrations and validated by evaluating the calibration model as well as the accuracy and precision. The models were applied to commercial preparations (Ticlid). The results were compared to those obtained from the application of HPLC using the methodology described by "Sanofi Research Department" and were found to be in excellent agreement, proving that NIR, using fiber-optic probes, and FT-Raman spectroscopy can be used for the fast and reliable determination of the major component in pharmaceutical analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18284803     DOI: 10.1366/000370208783575636

Source DB:  PubMed          Journal:  Appl Spectrosc        ISSN: 0003-7028            Impact factor:   2.388


  1 in total

1.  Development and validation of a stability indicating UPLC method for determination of ticlopidine hydrochloride in its tablet formulation.

Authors:  Vijay Ram; Govind Kher; Kapil Dubal; Bhavesh Dodiya; Hitendra Joshi
Journal:  Saudi Pharm J       Date:  2011-03-21       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.